Ali Zeaiter, Head of Oncology Clinical Development at Pierre Fabre Laboratories, shared on LinkedIn:
“I am delighted to share that I have joined Pierre Fabre Laboratories, taking on a new leadership role in Oncology.
This is an exciting opportunity to join a company with a strong heritage in oncology and an ambitious vision for the future: to accelerate precision oncology and bring the right treatment to the right patient.
Pierre Fabre is entering an important new phase in its oncology journey, with precision oncology at the heart of its R/D strategy and growth ambition. Its focus on targeted therapies, innovative approaches and strategic partnerships reflects the transformation taking place across cancer drug development.
After more than 20 years in the pharmaceutical industry, with a particular focus on global clinical development and oncology, I am particularly excited to contribute to this journey – translating promising science into robust clinical development strategies and, ultimately, meaningful benefits for patients.
I look forward to working with talented colleagues across Pierre Fabre and with our partners in the oncology ecosystem to advance innovative medicines for patients with significant unmet medical needs.
A new chapter, with the same purpose: advancing science and improving outcomes for patients.”
Other articles about Pierre Fabre on OncoDaily.